Background: Cervical cancer is largely preventable through HPV vaccination and screening yet remains a major cause of morbidity and mortality where coverage is incomplete. Mapping prevention and management evidence is critical to inform scale-up toward WHO elimination targets. Objectives: To map recent evidence (2010–10 Aug 2025) on primary prevention, screening (including self-sampling), and clinical management of cervical cancer; identify implementation gaps; and highlight priorities for practice and research. Methods: PRISMA-ScR–framed scoping review. A reproducible PubMed search (see Methods) was run 10 Aug 2025; the top 300 PubMed results were retrieved, deduplicated and screened (title/abstract, full text) using predefined eligibility criteria (English; 2010–01–01 to 2025-08-10). Thematic charting and synthesis summarised policy and empirical literature. PRISMA-ScR flow counts are provided. Results: From 300 PubMed records retrieved, 22 sources met inclusion criteria (see PRISMA flow and included-studies table). Key findings: (1) WHO and major authorities support simplified HPV vaccine schedules (one- or two-dose approaches) with ongoing rollout variability; (2) momentum toward HPV primary testing and self-sampling to reach under-screened groups with robust evidence that self-sampling increases uptake; (3) established treatment pathways (thermal ablation/cryotherapy for precancerous lesions, surgery/chemoradiation for invasive disease) are constrained by referral and resource gaps in many settings. Implementation research priorities include linkage-to-treatment, cost-effectiveness of self-sampling programs, and equitable vaccine scale-up. Conclusions: Current prevention and management tools can achieve substantial cervical cancer control and set countries on a path to elimination if vaccination and high-quality screening with effective treatment linkage are scaled equitably.